PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business

Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal

Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.

7sources
7articles
5velocity
+65%since first seen
50d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

Merck and Daiichi Sankyo voluntarily retracted and scraped their FDA accelerated approval application and biologics license application for their partnered B7-H3 antibody-drug conjugate in previously treated extensive-stage small-cell lung cancer. This withdrawal followed regulatory pushback, marking another blow to their four-billion-dollar deal and prompting analysis regarding the valuation of Daiichi Sankyo Company.

Epilogue added 47d ago, after coverage quieted.

The brief

Recent coverage from BioSpace, FirstWord, simplywall.st, Endpoints News, OncLive, Reuters, and Fierce Biotech details that Merck and Daiichi Sankyo have voluntarily withdrawn their accelerated approval request and biologics license application for ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer. This regulatory setback follows pushback from the United States Food and Drug Administration. The withdrawn application represents the second partnered cancer therapy application pulled by the companies, creating further challenges for their multi-billion dollar partnership. Media reports and analytical commentary emphasize the significance of this development for the companies' joint oncology pipeline.

Publications such as FirstWord and Fierce Biotech frame the withdrawal as another major obstacle following previous difficulties in their alliance. Financial commentary from simplywall.st questions the valuation implications for Daiichi Sankyo Company following the regulatory setback, while OncLive and Endpoints News provide specific clinical context regarding the target, identifying the therapy as a B7-H3 antibody-drug conjugate. Context provided across the reporting highlights that this application withdrawal directly impacts the broad partnership between the two pharmaceutical firms. The overarching alliance, valued in the coverage at four billion dollars, has faced repeated hurdles regarding regulatory approvals for its antibody-drug conjugate assets.

While prior coverage does not yet specify the exact nature of the regulatory feedback or the precise clinical data points that triggered the Food and Drug Administration pushback, the voluntary withdrawal effectively halts the current review process for this specific indication. Looking ahead, coverage does not yet specify whether the companies intend to resubmit the application or pursue alternative clinical pathways for ifinatamab deruxtecan. Observers and market participants will monitor upcoming corporate communications from Merck and Daiichi Sankyo for further details regarding the future of their shared oncology portfolio and the broader implications for their multi-billion dollar collaboration agreement following this dual setback.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 48d ago.

Quick answers

Which companies are involved in the withdrawn application?

Merck and Daiichi Sankyo are the partners involved in the application.

What specific drug and indication were targeted?

The application involved ifinatamab deruxtecan, a B7-H3 antibody-drug conjugate for previously treated extensive-stage small cell lung cancer.

What outlets covered the trend?

Coverage was provided by BioSpace, FirstWord, simplywall.st, Endpoints News, OncLive, Reuters, and Fierce Biotech.

Coverage (7)

Topics

Related trends

▲ Peaking Business

The GLP-1 boom has a dark side

FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.

5 sources 5 articles v 14 1d ago
\n \n \n \n \n \n \n